AMMAN — AstraZeneca Jordan on Monday evening
underlined its commitment to cooperate with the Jordanian government to curb
the impact of the COVID-19 pandemic in an interview with the Jordan News
Agency, Petra.
اضافة اعلان
Abdulkareem Dissi, the pharmaceutical's regional director
said that the company is actively working with international organizations,
governments, healthcare leaders, and industry and civil society to end the
pandemic, stressing the need to continue cooperation with the Jordanian
government to that end.
AstraZeneca’s partnership with the Jordanian government has led to the delivery
of more than 600,000 doses of the COVID-19 vaccine to date. "Thousands of
lives are being saved every day as a result of such urgent and committed
cooperation," Dissi said.
He also lauded the efforts exerted by His Majesty King Abdullah and the
government throughout the pandemic to provide the appropriate infrastructure,
hospitals, and immunization centers, in addition to launching awareness
campaigns on the vaccine.
"Recognizing the urgent need for an effective COVID-19 vaccine to help
defeat the virus, we joined forces with the University of Oxford in April 2020
to make a meaningful difference to the course of the pandemic and help save
lives,” Dissi said. “This landmark partnership brought together Oxford
University’s world-class expertise in vaccinology with AstraZeneca’s global
development and manufacturing capabilities. Together we committed to providing
the vaccine broadly and equitably around the world, at no profit during the
pandemic period."
To help meet global demand for a
COVID-19 vaccine, AstraZeneca rapidly
conducted due diligence with more than 60 potential partners to ultimately
build a global supply network of more than 25 proven manufacturing
organizations in 15 countries with the capability and capacity to supply the
vaccine, he added.
On vaccine safety, Dissi said: "Ensuring the safety of our vaccine is
paramount and we are actively working with the regulators and scientific
community to understand extremely rare blood clotting events that have been
reported, including information to drive early diagnosis and intervention, and
appropriate treatment for the condition."
He added that the company had partnered with different organizations with
large-scale manufacturing capabilities to ensure that the vaccine could be
manufactured on a larger scale and reach people in need as quickly as possible.
Read more National news
.jpg)
.jpg)
